David Reardon

David Reardon

Company: Dana-Faber Cancer Institute

Job title: Clinical Director, Center for Neuro- Oncology

Seminars:

Neoantigen Vaccination for Glioblastoma: Does Timing of Anti-PD-1 Matter? 10:00 am

• Better understand the rationale of combining neoantigen vaccination with anti-PD-1 therapy; • Gain awareness of increasing preclinical data implicating how the timing of anti-PD-1 therapy may impact on anti-tumor immune responses generated by neoantigen vaccination; • Appreciate the challenges of assessing the impact of anti-PD-1 timing on anti-tumor immune responses generated by neoantigen vaccination…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.